DNA Methyltransferase Inhibitor and Rapamycin Synergistically Modulate Cell Cycle and Mammalian Target of Rapamycin Signaling Pathway for Human Colorectal Cancer Cells

Yanjie Zhang,Jing‐Yuan Fang,Qiang Jin,Shuliang Zhao,Da Sun,Guan-Feng Shen

2007-01-01

Abstract:Objective To investigate the synergistic effect of 5-aza-2＇-deoxycytidine （5-aza-dC） and rapamycin （RPM） on human colorectal cancer cells and it＇s potential mechanisms. Methods Three human colorectal cancer cell lines SW480, HT29 and HCTI 16 were treated for 48 h with 5-aza-dC, RPM, or 5-aza-dC plus RPM, respectively, and the sensitivity was analysed by an MTT assay. Western blotting analysis was performed to examine the total and phosphorylated levels of mammalian target of rapamycin （mTOR） and its downstream translational signalling intermediates, 70 kDa ribosomal protein $6 kinase （p70s6k） and eukaryotic initiation factor 4E-binding protein 1 （4E-BP1）. The cell cycle progression was evaluated by flow cytometry. Results Both 5-aza-dC and RPM could inhibit viability of three colorectal cancer cell lines, which effect was more significantly in cells treated with 5-aza-dC plus RPM than that 5-aza-dC or RPM only. Treated with 5-aza-dC, RPM, and 5-aza-dC plus RPM all induced blockage of cell cycle progression, although the arrest was confined to different cell cycle phases. In addition to their effect on proliferation and cell cycle, both inhibitors also reduced phosphorylation levels of mTOR, p70s6k, and 4E-BP1, which effect was reinforced when treated cells with 5-aza-dC plus RPM simultaneously, whereas total protein levels remained unchanged. Conclusion 5-aza-dC and RPM inhibit proliferation of colorectal cancer cells synergistically, and induce cell cycle arrest. The potential mechanisms involve modulation of mammalian target of rapamycin signaling pathway. Key words: 5-aza-2＇-deoxycytidine ; Rapamycin ; Colorectal cancer ; Signal transduction